Cytocidal Effect of Irradiation on Gastric Cancer Cells Infected with a Recombinant Mammalian Orthoreovirus Expressing a Membrane-Targeted KillerRed
Authors:
Open Access
- 8 January 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (1) , 79
Abstract
The outcomes of unresectable gastric cancer (GC) are unfavorable even with chemotherapy; therefore, a new treatment modality is required. The combination of an oncolytic virus and photodynamic therapy can be one of the promising modalities to overcome this. Mammalian orthoreovirus (MRV) is an oncolytic virus that has been used in clinical trials for several cancers. In this study, we developed and evaluated a recombinant MRV strain type 3 Dearing (T3D) that expresses membrane-targeting KillerRed (KRmem), a phototoxic fluorescent protein that produces cytotoxic reactive oxygen species upon light irradiation. KRmem was fused in-frame to the 3′ end of the σ2 viral gene in the S2 segment using a 2A peptide linker, enabling the expression of multiple proteins from a single transcript. RNA electrophoresis, Western blotting, and immunofluorescence analyses confirmed functional insertion of KRmem into the recombinant virus. The growth activity of the recombinant virus was comparable to that of the wild-type MRV in a cultured cell line. The recombinant virus infected two GC cell lines (MKN45P and MKN7), and a significant cytocidal effect was observed in MKN45P cells infected with the recombinant virus after light irradiation. Thus, recombinant MRV-expressing KRmem has the potential to serve as a novel treatment tool for GC.Keywords
Funding Information
- Japan Society for the Promotion of Science (JSPS) Kakenhi (20K09082, 23H02983)
This publication has 54 references indexed in Scilit:
- Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expressionProceedings of the National Academy of Sciences, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cellsInternational Journal of Cancer, 2012
- Isolation of Reovirus T3D Mutants Capable of Infecting Human Tumor Cells Independent of Junction Adhesion Molecule-APLOS ONE, 2012
- Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathwayBMC Cancer, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cellsMolecular Cancer, 2009
- Structure of Reovirus σ1 in Complex with Its Receptor Junctional Adhesion Molecule-APLOS Pathogens, 2008
- Features of the mammalian orthoreovirus 3 Dearing l1 single-stranded RNA that direct packaging and serotype restrictionJournal of General Virology, 2007
- A Plasmid-Based Reverse Genetics System for Animal Double-Stranded RNA VirusesCell Host & Microbe, 2007